FDAnews Device Daily Bulletin

Entac Medical Secures Series A Funding

Jan. 6, 2016

Entac Medical has snapped up an undisclosed sum in Series A financing to support the development of its PrevisEA, a noninvasive technology that detects a biological signal correlated with the development of gastrointestinal impairment.

The funding round — which remains open until Jan. 31 — is being led by Innova Memphis. Co-investors include Angel Syndicates Central and the Angel Round Table. Entac says it already has surpassed its initial funding objectives.

The biological signals primarily include postoperative ileus, an acute paralysis of the gastrointestinal tract causing nausea, vomiting, abdominal distention and pain. — Michael Cipriano